SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea flag South Korea · Delayed Price · Currency is KRW
116,000
-3,500 (-2.93%)
Nov 7, 2025, 3:30 PM KST
-2.93%
Market Cap9.08T
Revenue (ttm)620.28B
Net Income (ttm)255.99B
Shares Out78.31M
EPS (ttm)3,268.81
PE Ratio35.49
Forward PE41.28
Dividendn/a
Ex-Dividend Daten/a
Volume335,206
Average Volume298,463
Open117,400
Previous Close119,500
Day's Range114,000 - 119,500
52-Week Range86,900 - 129,800
Beta0.83
RSI59.61
Earnings DateNov 5, 2025

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilep... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 246
Stock Exchange Korea Stock Exchange
Ticker Symbol 326030
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.